Susquehanna Fundamental Investments LLC Purchases New Holdings in Merck & Co., Inc. $MRK

Susquehanna Fundamental Investments LLC acquired a new position in Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 89,259 shares of the company’s stock, valued at approximately $11,470,000.

Other large investors have also modified their holdings of the company. Cascade Financial Partners LLC boosted its stake in shares of Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after purchasing an additional 80 shares during the period. Somerset Trust Co increased its position in shares of Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after acquiring an additional 81 shares during the period. Stonebridge Financial Group LLC raised its stake in shares of Merck & Co., Inc. by 0.9% during the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after acquiring an additional 81 shares in the last quarter. Stronghold Wealth Management L.L.C. raised its stake in shares of Merck & Co., Inc. by 2.6% during the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after acquiring an additional 82 shares in the last quarter. Finally, Lederer & Associates Investment Counsel CA boosted its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock valued at $1,234,000 after purchasing an additional 84 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $148.30 on Monday. The stock’s 50-day moving average is $131.78 and its 200 day moving average is $122.45. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a market cap of $365.88 billion, a P/E ratio of 118.64, a PEG ratio of 6.22 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Analysts Set New Price Targets

MRK has been the topic of several research reports. Royal Bank Of Canada downgraded Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and raised their price objective for the stock from $142.00 to $150.00 in a report on Thursday, August 20th. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a report on Wednesday, August 12th. Scotiabank raised their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a report on Monday, July 6th. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $147.60.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 over the last three months. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.